Donnadieu N, Paesmans M, Sculier JP: Chemotherapy of non-small cell lung cancer according to disease extent: a meta-analysis of the literature. Lung Cancer 7: 243-252, 1991.
Gehan EA: The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13: 346-353, 1961.
Crawford J, O'Rourke M, Schiller JH, Harris Spiridonitis C, Yanovich S, Ozer H, Langleben A, Hutchins L, Clamon G, Burman S, White R, Hohneker J: Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J Clin Oncol 14: 2774-2784, 1996.
Furuse K, Fukuoka M, Kuba M, Yamori S, Nakai Y, Negoro S, Katagami N, Takada Y, Kinuwaki E, Kubota K, Sakuma A, Niitani H.' Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC). Ann Oncol 7: 815-820, 1996.
Furuse K, Kubota K, Kawahara M, Ogawara M, Kinuwaki E, Motomiya M, Nishiwaki Y, Niitani H, Sakuma A: A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Lung Cancer 11: 385-391, 1994.
Veronesi A, Crivellari D, Cartei G, Mansutti M, Foladore S, Monfardini S: Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. EurJ Cancer 32A: 1809-1811, 1996.
Depierre A, Chastang C, Quoix E, Lebeau B, Blanchon F, Paillot N, Lemarie E, Milleron B, Moro D, Clavier J, Herman D, Tuchais E, Jacoulet P, Brechot JM, Cordier JF, Solal-Celigny P, Badry N, Besenval M: Vinorelbine versus vinorelbine plus cisplatin in advanced non-small cell lung cancer: a randomized trial. Ann Oncol 5: 37-42, 1994.
Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC: Efficacity of Navelbine® (NVB) in non-small cell lung cancer (NSCLC). Sem Oncol 16: 26-29, 1989.
Gridelli G, Perrone F, Gallo C, De Marinis F, Ianniello G, Cigolari S, Cariello S, Di Costanzo F, D'Aprile M, Rossi A, Migliorino R, Bartolucci R, Bianco AR, Pergola M, Monfardini S: Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study. Eur J Cancer 33: 392-397, 1997.
Carrato A, Rosell R, Camps C, Anton A, Garcia-Gomez R, Aranda E, Massuti B, Diaz-Fernandez N, Sanchez JJ, Garcia-Paredes ML' Modified weekly regimen with vinorelbine as a single agent in unresectable non-small cell lung cancer. Lung Cancer 17: 261-269, 1997.
Clerici M, Bretti S, Celano A, Panvini D, Comandone A, Casadio C, Luporini G,. Bumma C: Non small cell lung cancer treatment with vinorelbine monochemotherapy: a phase II study. Anticancer Res 15: 477-478, 1995.
Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S, Gottfried M, Ruffie P, Panizo A, Gaspard MH, Ravaioli A, Besenval M, Besson F, Martinez A, Berthaud P, Tursz T: Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367, 1994.
Bretti S, Berruti A, Gorzegno G, La Ciura P, Paze E, Celano A, Grecchi G, Perroni D, Bumma C, Dogliotti L: Multicenter phase II trial of intermediate dose cisplatin and vinorelbine in inoperable non-small-cell lung cancer patients. Lung Cancer 14: 353-360, 1996.
Westeel V, Jacoulet P, Breton JL, Garnier G, Mercier M, Depierre A: Phase II study of alternating doses of vinorelbine in combination with cisplatin for non-small cell lung cancer (NSCLC): a disappointing experience. Lung Cancer 16: 61-73, 1996.
Gebbia V, Caruso M, Valenza R, Testa A, Cannata G, Verderame F, Cipolla C, Curto G, Oliveri D, Chiarenza M, Latteri MA, Di Gesu G, Gebbia N: Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung carcinoma. Anticancer Res 14: 1247-1250, 1994.
Baldini E, Tibaldi C, Chella A, Angeletti CA, Silvano G, Andrei A, Algeri R, Conte PF: Phase II study of vinorelbine/ ifosfamide/cisplatin for the treatment of advanced non-small-cell lung cancer. Ann Oncol 7: 747-749, 1996.
Morere JF, Piperno-Neumann S, Brunet A, Boaziz C, Kohn M, Bouillet T, Breau JL: Vinorelbine and ifosfamide for unresectable non-small cell lung cancer. Lung Cancer 18: 95-100, 1997.
Pronzato P, Ghio E, Losardo PL, Landucci M, Vaira F, Vigani A. Carboplatin and vinorelbine in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 37: 610-612, 1996.
Pronzato P, Landucci M, Vaira F, Vigani A, Bertelli G: Failure of vinorelbine to reduce responses in pretreated non-small cell lung cancer patients. Anticancer Res 14: 1413-1416, 1994.
Vokes EE, Rosenberg RK, Jahanzeb M, Craig JB, Gralla RJ, Belani CP, Jones SE, Bigley JW, Hohneker JA: Multicenter phase II study of weekly oral vinorelbine for stage IV non-small-cell lung cancer. J Clin Oncol 13: 637-644, 1995.
Iaffaioli RV, Caponigro F, Tortoriello A, Facchini G, Ravo V, Maccauro M, Dimitri P, Crovella F, Muto P: Accelerated split-course (type B) thoracic radiation therapy plus vinorelbine/ carboplatin combination chemotherapy in stage III inoperable non-small cell lung cancer. Eur J Cancer 32A: 1901-1904, 1996.
Gatzemeier U, Heckmayr M, Neuhauss R, Schluter I, Pawel JV, Wagner H, Dreps A-Phase II study with paclitaxel for the treatment of advanced inoperable non-small cell lung cancer. Lung Cancer 12: S101-S106, 1995.
Furuse K, Naka N, Takada M, Kinuwaki E, Kudo S, Takada Y, Yamakido M, Yamamoto H, Fukuoka M: Phase II study of 3-hour infusion of paclitaxel in patients with previously untreated stage III and IV non-small cell lung cancer. Oncology 54: 298-303, 1997.
Tester WJ, Jin PY, Reardon DH, Cohn JB, Cohen MH: Phase II study of patients with metastatic non-small cell carcinoma of the lung treated with paclitaxel by 3-hour infusion. Cancer 79: 724-729, 1997.
Millward MJ, Bishop JF, Friedlander M, Levi JA, Goldstein D, Olver IN, Smith JG, Toner GC, Rischin D, Bell DR: Phase II trial of a 3-hour infusion of paclitaxel in previously untreated patients with advanced non-small-cell lung cancer. J Clin Oncol 14: 142-148, 1996.
Hainsworth D, Thompson DS, Greco FA: Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13: 1609-1614, 1995.
Chang AY, Kim K, Glick J, Anderson T, Karp D, Johnson D: Phase II study of taxol, merbarone, and piroxantrone in stage IV non-small-cell lung cancer: the Eastern Cooperative Oncology Group results. J Natl Cancer Inst 85: 388-394, 1993.
Murphy WK, Fossella FV, Winn RJ, Shin DM, Hynes HE, Gross HM, Davilla E, Leimert J, Dhingra H, Raber MN, Krakoff IH, Hong WK: Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer. J Natl Cancer Inst 85: 384-388, 1993.
Kosmidis PA, Mylonakis N, Fountzilas G, Samantas E, Athanasiadis A, Andreopoulos E, Pavlidis N, Skarlos D: Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study. Ann Oncol 8: 697-699, 1997.
Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M, DeVore III Russel F: Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 14: 2054-2060, 1996.
Evans WK, Earle CC, Stewart DJ, Dahrouge S, Tomiak E, Goss G, Logan D, Goel R, Gertler SZ, Dulude H: Phase II study of a one hour paclitaxel infusion in combination with carboplatin for advanced non-small cell lung cancer. Lung Cancer 18: 83-94, 1997.
Langer CJ, Leighton JC, Comis RL, O'Dwyer PJ, McAleer CA, Bonjo CA, Engstrom PF, Litwin S, Ozols RF: Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 13: 1860-1870, 1995.
Stewart DJ, Tomiak EM, Goss G, Gertler SZ, Logan D, Huan S, Yau J, Dulude H, Evans WK: Paclitaxel plus hydroxyurea as second line therapy for non-small cell lung cancer. Lung Cancer 15: 115-123, 1996.
Greco FA, Stroup SL, Gray JR, Hainsworth JD: Paclitaxel in combination chemotherapy with radiotherapy in patients with unresectable stage III non-small-cell lung cancer. J Clin Oncol 14: 1642-1648, 1996.
Pirker R, Krajnik G, Zochbauer S, Malayeri R, Kneussl M, Huber H: Paclitaxel/cisplatin in advanced non-small-cell lung cancer (NSCLC). Ann Oncol 6: 833-835, 1995.
Lund B, Ryberg M, Meidahl Petersen P, Anderson H, Thatcher N, Dombernowsky P: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol 5: 852-853, 1994.
Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH: Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821-1826, 1994.
Abratt RP, Hacking DJ, Goedhals L, Bezwoda WR: Weekly gemcitabine and monthly cisplatin for advanced non-small cell lung carcinoma. Sem Oncol 24: S8-18-S8-23, 1997.
Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540, 1994.
Gatzemeier U, Manegold C, Eberhard W, Wilke HJ, Chomy F, Chomy P, Khayat D, Blatter J, Seeber S, Drings P: A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer. Sem Oncol 24: S8-36-S8-38, 1997.
Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJM, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M, Voi M: Activity of gemcitabine in patients with non-small cell lung cancer: a multicenter, extended phase II study. Eur J Cancer 32A: 243-248, 1996.
Halme M, Jekunen A, Tamminen K, Mattson K: Phase II study of weekly gemcitabine in advanced non-small cell lung cancer. Respir Med 91: 423-426, 1997.
Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, De Marinis F, Salvati F, Cruciani G, Dogliotti L, Pucci F, Paccagnella A, Adamo V, Altavilla G, Incoronato P, Trippetti M, Mosconi AM, Santucci A, Sorbolini S, Oliva C, Tonato M: Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 15: 297-303, 1997.
Shepherd FA, Cormier Y, Burkes R, Evans WK, Goss G, Klimo P, Feld R, Taylor M. Phase II trial of gemcitabine and weekly cisplatin for advanced non-small cell lung cancer. Sem Oncol 24: S8-27-S8-30, 1997.
Manegold C, Bergman B, Chemaissani A, Dornof W, Drings P, Kellokumpu-Lehtinen P, Liipo K, Mattson K, Pawel Jv, Ricci S, Sederholm C, Stahel RA, Wagenius G, Walree Nv, ten Bokkel-Huinink W: Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 8: 525-529, 1997.
Perng RP, Chen YM, Ming-Liu J, Tsai CM, Lin WC, Yang KY, Whang-Peng J: Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 15: 2097-2102, 1997.
Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R, Murphy WK, Lippman S, Benner S, Glisson B, Chasen M, Hong WK, Raber M: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13: 645-651, 1995.
Fossella FV, Lee JS, Murphy WK, Lippman SM, Calayag M, Pang A, Chasen M, Shin DM, Glisson B, Benner S, Huber M, Perez-Soler R, Hong WK, Raber M: Phase II study of docetaxel for recurrent or metastatic non-small-cell lung cancer. J Clin Oncol 12: 1238-1244, 1994.
Cerny T, Kaplan S, Pavlidis N, Schoffski P, Epelbaum R, van Meerbeek J, Wanders J, Franklin HR, Kaye S: Docetaxel (Taxotere™) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). Br J Cancer 70: 384-387, 1994.
Francis PA, Rigas JR, Kris MG, Pisters KMW, Orazem JP, Woolley KJ, Heelan RT: Phase II trial of docetaxel in patients with stage III and IV non-small-cell lung cancer. J Clin Oncol 12: 1232-1237, 1994.
Miller VA, Rigas JR, Francis PA, Grant SC, Pisters KMW, Venkatraman ES, Woolley K, Heelan RT, Kris MG: Phase II trial of a 75-mg/m2 dose of docetaxel with prednisone premedication for patients with advanced non-small cell lung cancer. Cancer 75: 968-972, 1995.
Kunitoh H, Watanabe K, Onoshi T, Furuse K, Niitani H, Taguchi T: Phase II trial of docetaxel in previously untreated advanced non-small-cell lung cancer: a Japanese cooperative study. J Clin Oncol 14: 1649-1655, 1996.
Lynch TJ, Kalish L, Strauss G, Elias A, Skarin A, Shulman LN, Posner M, Frei III E: Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 12: 347-352, 1994.
Perez-Soler R, Fossella FV, Glisson BS, Lee JS, Murphy WK, Shin DM, Kemp BL, Lee JJ, Kane J, Robinson RA, Lippman SM, Kurie JM, Huber MH, Raber MN, Hong WK: Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 14: 503-513, 1996.
Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T: A phase II study of CPT-, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16-20, 1992.
Oshita F, Noda K, Nishiwaki Y, Fujita A, Kurita Y, Nakabayashi T, Tobise K, Abe S, Suzuki S, Hayashi I, Kawakami Y, Matsuda T, Tsuchiya S, Takahashi S, Tamura T, Saijo N: Phase II study of irinotecan and etoposide in patients with metastatic non-small-cell lung cancer. J Clin Oncol 15: 304-309, 1997.
Sculier JP, Berghmans T, Castaigne C, Luce S, Sotiriou C, Vermylen P, Paesmans M: Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer 19: 141-151, 1998.
Chalmers TC, Smith H Jr, Blackburn B, Silverman B, Schroeder B, Reitman D, et al: A method for assessing the quality of a randomized clinical trial. Control Clin Trials 2: 31-49, 1981.
